Target intelligence / Profile preview

Taurine up-regulated gene 1 (long non-coding RNA) (TUG1)

Target
TUG1
Molecular classification
Long non-coding RNA (lncRNA), Other (not a protein, receptor, enzyme, transporter, or ion channel)
01

Overview

Taurine up-regulated gene 1 (TUG1) is a well-studied long non-coding RNA (lncRNA) originally identified as being upregulated by taurine treatment in developing retinal cells. It does not encode a protein. TUG1 serves as a molecular regulator in a wide variety of biological processes, particularly in cancers, where it is frequently abnormally expressed. It facilitates tumor progression by modulating cell proliferation, invasion, migration, apoptosis, cell cycle, and drug resistance. Mechanistically, TUG1 functions through a combination of acting as a sponge for tumor-suppressive microRNAs (such as miR-143-5p and miR-498), recruiting RNA-binding proteins for chromatin remodeling, and influencing gene transcription and genome stability through R-loop regulation. TUG1’s expression levels correlate with clinical prognosis and therapeutic response in multiple cancer types and are thus viewed as potential biomarkers and therapeutic targets. However, context-specific effects—including both oncogenic and tumor-suppressive properties—have been reported, and direct therapeutic targeting is primarily investigational, focusing on nucleic acid–based strategies rather than small molecules.

Other names
Taurine up-regulated gene 1TUG1FLJ20618NCRNA00080LINC00080non-protein coding RNA 80long intergenic non-protein coding RNA 80TI-227Htaurine upregulated gene 1
02

Mechanism of action

Acts as a competing endogenous RNA (ceRNA), sponging specific microRNAs (e.g., miR-143-5p, miR-498) Interacts with and recruits RNA-binding proteins (e.g., heterogeneous nuclear ribonucleoproteins, poly(ADP-ribose) polymerase 1) Epigenetic regulation of gene expression, including histone modification complexes Influences angiogenesis and cell signaling in cancer progression

03

Biological functions

Regulation of gene expression (epigenetic, transcriptional, and post-transcriptional modulation)Regulation of cell proliferationApoptosis (both promotion and inhibition depending on context)Cell migration and invasionRegulation of cell cycleDrug resistanceGenome integrity maintenance (via R-loop resolution)Regulation of mitochondrial bioenergetics (context-dependent)
04

Disease associations

Cancer (multiple types: osteosarcoma, esophageal cancer, gastric cancer, NSCLC, glioma, among others)Cardiovascular diseaseNeurodegenerative disease (limited evidence, e.g., some studies in retinal cells and neuronal biology)Metabolic disease, such as diabetic nephropathy (via regulation of mitochondrial activity in podocytes)
05

Safety considerations

The primary safety and therapeutic challenges concern delivery and specificity for targeting lncRNAs, as well as potential off-target effects and the context-dependent dual roles of TUG1 (oncogenic or tumor-suppressive depending on tissue/cell type)Effective in vivo delivery of nucleic acid–based therapeutics remains a major translational challenge
06

Interacting drugs

No specific small molecule or drug directly targeting TUG1 is approved or widely recognized in clinical use as of the latest literature. Experimental modulation is mainly achieved via nucleic acid–based approaches (e.g., siRNA, antisense oligonucleotides)
07

Biomarkers

TUG1 expression levels serve as a diagnostic, prognostic, and predictive biomarker in several cancers, being associated with tumor size, stage, prognosis, and chemoresistance

Beyond the preview

Go deeper on Taurine up-regulated gene 1 (long non-coding RNA) (TUG1).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Taurine up-regulated gene 1 (long non-coding RNA) (TUG1).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call